Quantcast

Latest Sirolimus Stories

2010-11-23 07:00:00

HONG KONG, Nov. 23, 2010 /PRNewswire/ -- OrbusNeich today announced that data from two studies demonstrate that the Genous Stent increases endothelial coverage and reduces thrombogenicity as compared to bare metal stents (BMS) by enhancing the specific binding of CD34+ endothelial progenitor cells (EPCs). Eric J. Duckers, M.D., Ph.D., of the Thoraxcenter at Erasmus University Medical Center in Rotterdam, The Netherlands, and co-investigators Saami Yazdani, Ph.D., and Renu Virmani, M.D.,...

2010-11-19 06:55:00

NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population. Consistent with previous analyses, axitinib demonstrated a generally...

2010-11-03 16:08:00

EAST HANOVER, N.J., Nov. 3, 2010 /PRNewswire/ -- The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor® (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS)(1,2). This study, which was previously presented at the 46th American Society of Clinical Oncology annual meeting, is the first prospective clinical...

2010-10-30 09:25:00

SILVER SPRING, Md., Oct. 30 /PRNewswire/ -- The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC. This type of tumor develops in approximately 15-20 percent of individuals with TSC, and typically becomes...

2010-10-29 21:40:00

EAST HANOVER, N.J., Oct. 29 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the U.S. Food and Drug Administration (FDA) has approved Afinitor® (everolimus) tablets for patients with subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS), who require therapeutic intervention but are not candidates for curative surgical resection(2). This accelerated approval of Afinitor is based...

2010-10-19 07:00:00

WOONSOCKET, R.I., Oct. 19 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal(TM) BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property...

2010-10-11 10:54:00

HONG KONG, Oct. 11 /PRNewswire/ -- OrbusNeich today reported the completion of patient enrollment in a randomized clinical study of its Genous Bio-engineered R stent at 11 sites in China. The primary objective of the 180 patient, controlled study is to demonstrate the safety and effectiveness of the Genous Bio-engineered R stent compared to the Medtronic Endeavor® Sprint stent in patients with symptoms of angina or myocardial ischemia. The primary endpoints are difference...

2010-09-30 02:58:00

WATERLOO, Belgium, September 30, 2010 /PRNewswire/ -- - SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Clinical Safety and Efficacy Measures With Both CYPHER(R) Stent and XIENCE V(R) Stent - Only CYPHER Stent has More Than 10 years of Clinical Safety Data in 70 Studies Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary...

2010-09-25 09:18:00

WASHINGTON, Sept. 25 /PRNewswire/ -- OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell (EPC) capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington. Genous Bio-engineered R stent is safe and effective in diabetic patients, elderly...

2010-09-24 06:38:00

WASHINGTON, Sept. 24 /PRNewswire/ -- OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America. "Completion of enrollment of this study represents a significant milestone as we look to validate the potential for the Combo Stent in a...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.